Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III, Multicenter, Partially Randomized, Open Label Trial Investigating Safety and Efficacy of On-demand and Prophylactic Treatment With BAY94-9027 in Severe Hemophilia A

NCT01580293 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01580293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01580293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III, Multicenter, Partially Randomized, Open Label Trial Investigating Safety and Efficacy of On-demand and Prophylactic Treatment With BAY94-9027 in Severe Hemophilia A
Lead sponsor
Bayer
Phase
Phase 2/3
Overall status
Completed
Start date
April 23, 2012
Completion date
November 21, 2019
Enrollment
145 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a